New oral appliance focuses on comfort, affordability
Respire Medical, a manufacturer of oral appliances for the treatment of snoring and sleep apnea, has introduced the Respire Blue Series. The product, which the
Respire Medical, a manufacturer of oral appliances for the treatment of snoring and sleep apnea, has introduced the Respire Blue Series. The product, which the
Medtronic has introduced the Artisan space maintenance system for bone grafting space maintenance in oral-maxillofacial applications. The device is cleared for temporary use in oral-maxillofacial
A multidisciplinary expert panel convened by the ADA’s Council on Scientific Affairs has issued a report containing clinical recommendations that support the use of certain
Manufacturers of bisphosphonate drugs such as Fosamax and Zometa should make changes to their product labeling to reduce the risk of bone fractures, two U.S.
Eligible adults are being invited to apply for Give Back A Smile (GBAS), a U.S. program that restores damaged smiles for survivors of domestic violence.
Lares Research is introducing Quest, a new line of American-made high-speed handpieces that will be available exclusively through national, regional, and local U.S. dental dealers.
Opalescence (Ultradent Products) was a sponsor of the 2011 Mrs. Globe Pageant on August 27, 2011, in Rancho Mirage, CA, where more 40 delegates from
ADELPHI, Md. (Reuters) – U.S. health advisers are considering a time limit for taking a class of drugs used by millions of women to prevent
Biomet 3i, a manufacturer of dental implants, abutments, and related products, has developed a free informational app for the iPad and iPhone, Android, and Blackberry
The Georgia Board of Dentistry wants to adopt a proposal requiring that hygienists who provide basic preventive dental services in schools, community health centers, and
It took a bevy of specialists and faculty members at the New York University (NYU) College of Dentistry to unravel the mystery of how a
Two U.S. Food and Drug Administration (FDA) advisory panels will meet this week to review the potential risks associated with long-term use of bisphosphonate medications